1. Canadian Cancer Society’s steering committee: Canadian Cancer Statistics 2009. Canadian Cancer Society, Toronto (2009)
2. Horner, M.J., Ries, L.A.G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., Altekruse, S.F., Feuer, E.J., Huang, L., Mariotto, A., Miller, B.A., Lewis, D.R., Eisner, M.P., Stinchcomb, D.G., Edwards, B.K. (eds.): SEER Cancer Statistics Review, 1975-2006. National Cancer Institute, Bethesda (2009), http://seer.cancer.gov/csr/1975_2006/
3. LaSpina, M., Haas, G.P.: Update on the diagnois and management of prostate cancer. Canadian Journal of Urology 15(suppl. 1), 3–13 (2008) (discussion 13)
4. Leite, K.R.M., Camara-Lopes, L.H.A., Dall’Oglio, M.F., Cury, J., Antunes, A.A., Sanudo, A., Srougi, M.: Upgrading the Gleason score in extended prostate biopsy: Implications for treatment choice. International Journal of Radiation Oncology Biology Physics 73, 353–356 (2009)
5. Ahmed, H.U., Kirkham, A., Arya, M., Illing, R., Freeman, A., Allen, C., Emberton, M.: Is it time to consider a role for MRI before prostate biopsy? Nature Reviews Clinical Oncology 6, 197–206 (2009)